Generex Biotechnology to Present Overview of Immuno-Oncology Development Program at Summit in Boston, MA

Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) is pleased to announce that Richard Purcell, the Company’s Executive Vice President of Research & Development will participate in a panel discussion at the Cambridge Healthtech Institute’s Immuno-Oncology Summit at the Seaport World Trade Center in Boston, MA (https://www.immuno-oncologysummit.com/) on August 30, 2018. The panel discussion will focus on current trends and future prospects for immunotherapy in the treatment of cancer. Additionally, Mr. Purcell will provide an overview of the relaunched clinical development program of the HER2/neu immunotherapeutic vaccine, AE37, together with strategies to advance the proprietary Ii-Key technology under development at the Company’s wholly-owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com).

“The introduction of checkpoint inhibitors has been revolutionary in the practice of clinical oncology, but is only effective in roughly 30% of patients across a variety of cancers,” said Mr. Purcell. “The complementary mechanism of action of AE37 (T-cell activation), and encouraging results obtained in triple negative breast cancer patients, strongly suggest that the combined use of AE37 with pembolizumab (Keytruda®) will provide significantly greater efficacy than either alone.”

The Immuno-Oncology Investing & Partnering Forum is taking place on Thursday, August 30^th and the session Novel Therapeutics in Cancer Immunotherapy will take place at 1:30 pm EDT and consist of company presentations followed by Q&A with the audience. The conference is taking place at the Seaport World Trade Center in Boston, MA, and the session room is Beacon Hill 1.

Cautionary Note Regarding Forward-Looking Statements

This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plan," "believes," "will," "achieve," "anticipate," "would," "should," "subject to" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180827005174/en/